RP-HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-24. Numbers and descriptions here follow the published literature rather than marketing material.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
=== Acting === Director Lal Jose noticed Kallingal on a magazine cover and approached her for a goat herder role in the Tamil film Mazhai Varappoguthu. The project did not go ahead, but director Shyamaprasad subsequently cast her in the lead female role of Varsha in Ritu (2009), which marked her acting debut. In 2009 she also appeared in the anthology film Kerala Cafe, in the segment Mrityunjayam, and in Neelathaamara directed by Lal Jose. In 2012, Kallingal was cast opposite Fahadh Faasil in 22 Female Kottayam, directed by Aashiq Abu, playing a nurse and rape survivor seeking justice. The film performed well commercially and won Kallingal the Kerala State Film Award for Best Actress and the Filmfare Award for Best Actress – Malayalam. The film also drew praise from critics; Sify wrote that Kallingal "poured her heart into her character" and delivered "a spectacular performance". In 2013, she hosted the Mazhavil Manorama reality show Midukki, following which the Kerala Film Chamber imposed a temporary ban on her for disregarding a recent notice by the chamber; the ban was subsequently revoked. That same year she played a housewife in August Club. Paresh C. Palicha of Rediff.com noted that Kallingal portrayed a character "who has learnt to stifle her feelings and finding other ways to give them an outlet". In 2015, she appeared alongside Manju Warrier in Rani Padmini, playing a disruptive North Indian woman on a road trip from Kerala to Shimla. The film was a commercial success and critic Deepa Soman described her performance as a "knockout".
According to Thompson, this term is the Assyrian name for the juice of the poppy and it may be the etymological origin of the Latin "papaver". The ancient Egyptians had some surgical instruments, as well as crude analgesics and sedatives, including possibly an extract prepared from the mandrake fruit. The use of preparations similar to opium in surgery is recorded in the Ebers Papyrus, an Egyptian medical papyrus written in the Eighteenth Dynasty. However, it is questionable whether opium itself was known in ancient Egypt. The Greek gods Hypnos (Sleep), Nyx (Night), and Thanatos (Death) were often depicted holding poppies. Prior to the introduction of opium to ancient India and China, these civilizations pioneered the use of cannabis incense and aconitum. c. 400 BC, the Sushruta Samhita (a text from the Indian subcontinent on Ayurvedic medicine and surgery) advocates the use of wine with incense of cannabis for anesthesia. By the 8th century AD, Arab traders had brought opium to India and China.
== Tissue Localization == Prepro-URP which is the precursor to the mature URP peptide is found in various tissues including specific parts of the brain such as frontal lobe and hypothalamus, and other peripheral tissues such as heart, kidneys, lungs, placenta, ovaries, and testes. In humans the amount of UII and URP gene expression are comparable except in the spinal cord where UII gene expression is much higher. In rats the UII gene expression is higher than the URP gene expression throughout the entire body. However, when the brains of the rats were tested, only the URP peptide was found making it the primary endogenous ligand in the brain. Unlike humans and rats, URP gene expression is found in mice spinal cords.
Sources: en.wikipedia.org
=== DNA test === The muscle-specific isoform of the dystrophin gene is composed of 79 exons, and DNA testing (blood test) and analysis can usually identify the specific type of mutation of the exon or exons that are affected. DNA testing confirms the diagnosis in most cases.
1993/695) Guy's and Lewisham National Health Service Trust Dissolution Order 1993 (S.I. 1993/696) Barts National Health Service Trust Dissolution Order 1993 (S.I. 1993/697) King's Healthcare National Health Service Trust (Establishment) Amendment Order 1993 (S.I. 1993/698)
=== In development === Several new drugs and treatments are under development for snakebite. For instance, the metal chelator dimercaprol has recently been shown to potently antagonize the activity of Zn2+-dependent snake venom metalloproteinases in vitro. New monoclonal antibodies, polymer gels and a small molecule inhibitor called Varespladib are in development. A core outcome set (minimal list of consensus outcomes that should be used in future intervention research) for snakebite in South Asia is being developed. In an article published in Nature in October 2025, a group led by researchers from the Technical University of Denmark has presented the possibility of a broad-spectrum antivenom that can work against the bites of many different snakes. They have developed an experimental polyvalent recombinant anti-venom that the authors claim to be capable of neutralising seven toxin families or subfamilies. A study conducted by Jacob Glanville used two antibodies taken from the memory B cells of blood from a "hyperimmune" donor, who had been deliberately bitten by many species of snake, to develop an antivenom "cocktail". Elapidae were the focus of the study, of which nineteen are classified as being the deadliest on Earth by the World Health Organization. Tested on mice, the antivenom cocktail prevented death from thirteen of the nineteen species, with partial protection observed from the other six.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.